Nouvelle déclaration d'incident
No de la demande: 2018-2303
Numéro de référence du titulaire d'homologation: USA-BAYERBAH-2018-US0017336 (Report 482578)
Nom du titulaire (nom légal complet, aucune abbréviation): Bayer inc
Adresse: 2920 Matheson BLVD
Ville: Mississaugua
État: ON
Pays: Canada
Code postal /Zip: L5W5R6
Incident chez un animal domestique
Pays: UNITED STATES
État: TENNESSEE
Inconnu
ARLA No d'homologation ARLA No de la demande d'homologation EPA No d'homologation. 11556-155
Nom du produit: Seresto Collar unknown
Autre (préciser)
COLLAROui
Autres unités: collar
Site: Animal / Usage sur un animal domestique
Inconnu
Propriétaire de l'animal
Cat / Chat
Unknown
1
Homme
Inconnu
Inconnu
Cutanée
Unknown / Inconnu
Unknown / Inconnu
Système
Persisted until death
Oui
Oui
2
Day(s) / Jour(s)
Mort
Treatment / Traitement
(p.ex. description des symptômes tels que la fréquence et la gravité
On 22 Apr 2018, the feline was squinting and lethargic. On 24 Apr 2018, the cat was anorexic. On 25 Apr 2018, the cat was examined by a local veterinarian. The feline was hyperthermic and was hospitalized, where treatment with unspecified intravenous antibiotics and a feeding tube placement was initiated. The feline was diagnosed with Cytauxzoon felis. The feline died on 27 Apr 2018 and no necropsy was performed. No further information is expected. Case is closed.
Mort
N - Unlikely Reported squinting is not expected with appropriate topical product application. Reported lethargy, anorexia and later reported hyperthermia are likely associated with diagnosed Cytauxzoon felis. In this case no ticks seen on cat. In case of attachment of ticks these will be killed and fall off the host within 24 to 48 hours after infestation without having had a blood meal, as a rule. However, attachment of single ticks and even sucking of blood and thus transfer of tick borne diseases cannot be excluded while the collar is worn and simply reflects the labeled claim of efficacy that is not 100% against ticks especially when infestation pressure is high. Thus, infection with tick borne diseases despite wearing a collar can occur exceptionally and is consistent with the product's claimed efficacy. Further, death is also not expected following appropriate topical product application as inconsistent with product's pharmacological profile. Oral exposure to the collar is not expected to cause serious signs either. Product has wide margin of safety. In this case time to onset is unknown for initially reported signs but it is long for reported death. Thus, other causes are more likely. Though necropsy was not performed, considering the known product profile sufficient information exists to conclude that the product did not cause the event and product involvement was ruled out. Hence, a product involvement is deemed to be unlikely.